AstraZeneca Pharma India Limited has submitted a regulatory disclosure addressed to both BSE Limited and the National Stock Exchange of India Ltd. The communication serves as an intimation of a scheduled interaction with an institutional investor.
The disclosure is made specifically pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The scheduled interaction is a one-on-one meeting with an institutional investor. It is set to take place virtually on Wednesday, August 26, 2026.
The company includes a disclaimer that the mentioned dates are subject to change. Such changes may occur due to exigencies on the part of either the Company or the Investor.
The letter is signed by Tanya Sanish, who holds the positions of Company Secretary and Compliance Officer for AstraZeneca Pharma India Limited. The document was digitally signed on August 21, 2026, at 22:09:01 IST.